Last updated: September 8, 2026

Tolazoline hydrochloride is a mature, low-revenue pharmaceutical with limited human use and a more durable veterinary niche. The U.S. human market is effectively legacy-based: historical indications included peripheral vascular disease and neonatal pulmonary hypertension, but modern therapies have displaced tolazoline in both settings. The principal commercial opportunity is veterinary injection, particularly reversal of xylazine sedation in horses. No meaningful active patent barrier protects the molecule, and no publicly reported standalone revenue supports a large branded-drug investment thesis.

What is the current market status of tolazoline hydrochloride?

Tolazoline hydrochloride is a nonselective alpha-adrenergic antagonist and vasodilator. It was developed for human cardiovascular and peripheral vascular indications and was later used in neonatal intensive care for pulmonary hypertension.

Its current market is divided into three segments:

Segment	Current commercial status	Competitive pressure
Human approved products	Historical or discontinued in the U.S.	Very high
Neonatal pulmonary hypertension	Legacy or off-label use	Inhaled nitric oxide, sildenafil, prostacyclin therapies
Veterinary medicine	Active niche, especially equine injection	Moderate, with limited direct substitutes

Tolazoline has a narrow commercial base because its historical human applications have been replaced by more selective, better-tolerated or better-supported therapies. Veterinary use remains commercially relevant because the drug can reverse xylazine-induced sedation in horses. The veterinary product is generally supplied as an injectable solution containing tolazoline hydrochloride at a concentration of approximately 100 mg/mL.

What are the principal approved and historical uses of tolazoline hydrochloride?

Human cardiovascular and peripheral vascular use

Historical human labeling covered vasospastic and peripheral vascular conditions. Tolazoline's pharmacology produced vasodilation, but its nonselective adrenergic activity also created gastrointestinal, cardiovascular and systemic adverse effects. The drug did not establish a durable position against newer vascular medicines.

Neonatal pulmonary hypertension

Tolazoline was used historically as a pulmonary vasodilator in newborns with persistent pulmonary hypertension. The therapy was limited by systemic hypotension, tachycardia and variable clinical response.

Inhaled nitric oxide became the dominant pharmacologic intervention for eligible term and near-term neonates with hypoxic respiratory failure and pulmonary hypertension. Sildenafil and prostacyclin-pathway therapies are used in selected cases, particularly in specialized centers. These alternatives reduced the addressable market for tolazoline substantially.[1][2]

Veterinary reversal of xylazine sedation

The active commercial use is veterinary. Tolazoline hydrochloride is administered to horses after xylazine sedation to accelerate recovery and reverse sedative effects. The product is used in equine practice, including ambulatory and surgical settings.

The market is small by human pharmaceutical standards but can be durable because:

equine practitioners continue to use alpha-2 agonists;
the reversal indication is operationally useful;
the product is supplied in an injectable presentation suited to veterinary clinics;
the product is not dependent on high-volume chronic prescribing.

When does tolazoline hydrochloride lose exclusivity?

Tolazoline hydrochloride lost practical molecule-level exclusivity decades ago. The compound was introduced in the mid-20th century, placing any original composition-of-matter or primary therapeutic-use patents well beyond their enforceable terms.

Exclusivity category	Current position
Original compound patent	Expired
Original human-use patents	Expired
U.S. regulatory exclusivity	No current commercially meaningful period identified
Formulation exclusivity	No material active barrier identified
Veterinary product exclusivity	Product-specific regulatory status, not broad molecule exclusivity
Data exclusivity	Not commercially significant for the mature molecule

No current patent estate appears capable of preventing generic or compounded production of tolazoline hydrochloride. Commercial protection depends on regulatory compliance, sterile manufacturing, distribution, veterinary relationships and supply continuity rather than patent rights.

What is the Orange Book status of tolazoline hydrochloride?

Tolazoline hydrochloride does not have the profile of an actively marketed, patent-protected human reference product in the current U.S. market.

The FDA Orange Book records therapeutic-equivalence information for approved prescription products, but an old or discontinued product does not automatically represent an active commercial reference product. The FDA's discontinued-drug records are relevant because a discontinued product may have been removed from the market for commercial reasons rather than safety or efficacy concerns.[3][4]

For tolazoline hydrochloride, the practical Orange Book conclusion is:

there is no active branded human franchise generating significant exclusivity value;
there is no current patent listing that creates a meaningful barrier to generic competition;
any U.S. human-market opportunity would depend on regulatory pathway, product availability and clinical demand;
veterinary products are governed through the FDA Center for Veterinary Medicine rather than the human Orange Book.

Are there Paragraph IV challenges to tolazoline hydrochloride?

No material current Paragraph IV litigation is associated with tolazoline hydrochloride.

Paragraph IV litigation typically arises when an ANDA applicant challenges listed patents covering an active reference drug. Tolazoline lacks the commercial characteristics that normally generate such litigation:

no high-revenue branded reference product;
no meaningful active patent estate;
no significant market exclusivity remaining;
limited human demand;
low expected damages from delayed generic entry.

A future applicant could face regulatory questions involving reference-product status, bioequivalence, injectable product quality and manufacturing controls. Those issues are more important than patent invalidity litigation.

What formulations are protected by tolazoline hydrochloride patents?

No commercially important active formulation patent barrier is evident for the standard injectable presentation.

The principal dosage form is an aqueous sterile injection. Key technical requirements include:

active pharmaceutical ingredient purity;
control of pH and osmolality;
sterility and endotoxin limits;
container-closure integrity;
particulate control;
stability throughout shelf life;
compatibility with the intended vial or ampule system.

These requirements can create manufacturing and approval costs, but they do not provide the same protection as an enforceable formulation patent. A manufacturer with an established sterile injectable platform may have a cost and reliability advantage even where the legal patent estate is weak.

How strong is the patent estate for tolazoline hydrochloride?

The patent estate is weak from an investment perspective.

Patent factor	Assessment
Composition-of-matter protection	Expired
Core method-of-use protection	Expired or commercially immaterial
Pediatric or neonatal use patents	No meaningful current exclusivity identified
Injectable formulation protection	No significant active barrier identified
Manufacturing patents	No market-blocking estate identified
Freedom-to-operate risk	Low for the active ingredient; higher for specific proprietary manufacturing processes

Tolazoline is therefore a low-IP product. Any commercial value lies in execution rather than exclusion. A supplier can gain practical defensibility through validated sterile production, reliable API sourcing, regulatory history and veterinary distribution, but those factors do not create broad legal exclusivity.

Which companies manufacture or commercialize tolazoline hydrochloride?

The best-established current commercial association is with veterinary manufacturers and distributors supplying tolazoline injection for equine use. In the United States, Tolazine has historically been associated with Lloyd Laboratories and the veterinary pharmaceutical distribution channel.[5]

The commercial landscape is fragmented:

veterinary branded or private-label injectables;
specialty distributors;
hospital or clinic procurement;
compounding pharmacies for limited human or veterinary requirements;
international manufacturers supplying active ingredient or finished dosage forms.

Public company filings generally do not break out tolazoline revenue. Sales are usually embedded within broader animal-health, equine or injectable-product categories. This prevents reliable calculation of a standalone market size from public financial statements.

What is the financial trajectory for tolazoline hydrochloride?

Tolazoline's financial trajectory differs sharply between the human and veterinary markets.

Human market trajectory

The human market declined over several decades as treatment moved toward:

inhaled nitric oxide for neonatal pulmonary hypertension;
sildenafil and other pulmonary vasodilators;
prostacyclin-pathway agents;
modern peripheral vascular and cardiovascular therapies;
intensive-care protocols with stronger clinical evidence.

Human revenue is now likely limited to isolated institutional demand, legacy use, international markets and compounding activity. It does not represent a conventional growth pharmaceutical opportunity.

Veterinary market trajectory

Veterinary demand is more stable but remains small. The market benefits from continued use of xylazine and the need for predictable recovery in horses. Growth is likely to track:

the number of equine procedures;
veterinary clinic utilization;
availability and pricing of xylazine;
product supply reliability;
competition from alternative reversal agents and clinical protocols.

The product has low chronic-prescription value. Revenue depends on procedure volume and stocking behavior rather than recurring monthly treatment.

Revenue exposure

Revenue driver	Directional impact
Human pulmonary hypertension use	Declining or negligible
Human peripheral vascular use	Negligible
Equine reversal use	Stable niche
Veterinary price increases	Limited by low-cost alternatives and clinic budgets
New indications	Unlikely without new clinical development
API or sterile-injectable supply disruption	Potential short-term price and share gains
Patent expiry	Minimal incremental impact because exclusivity is already absent

A realistic base case is a flat-to-declining human market and a stable, low-growth veterinary market. A high-growth scenario would require a supply shortage, new regulatory approval, or a re-emerging clinical use. None is currently evident as a durable market catalyst.

What regulatory barriers affect new tolazoline hydrochloride entrants?

The most significant barriers are regulatory and operational rather than patent-related.

Human injectable entry

A new U.S. human injectable product could require:

an approved application or other legally appropriate FDA pathway;
demonstration of pharmaceutical equivalence and product quality;
validated sterile manufacturing;
stability data;
container-closure testing;
labeling supported by the applicable regulatory record;
a suitable reference product if pursuing an abbreviated pathway.

The limited commercial demand may make development economics unattractive. A sterile injectable can require meaningful fixed investment even when the API is inexpensive.

Veterinary entry

A veterinary product requires compliance with FDA animal-drug requirements, including product quality, manufacturing controls, labeling and the applicable new animal drug pathway. A sponsor must also support the product's intended species, route and use conditions.

Veterinary approval can be commercially rational when the product fits an established equine distribution network. The addressable market remains too small to justify extensive clinical redevelopment unless a sponsor seeks a differentiated formulation or a broader animal-health platform.

What manufacturing and supply-chain risks affect tolazoline hydrochloride?

Tolazoline hydrochloride has a relatively simple active ingredient profile but can be difficult to commercialize consistently as a sterile injection.

API risks

Potential API risks include:

dependence on a limited number of qualified suppliers;
changes in pharmacopeial specifications;
impurity control;
batch-to-batch consistency;
limited demand that discourages redundant manufacturing capacity.

Finished-product risks

Sterile injectable manufacturing creates higher operational risk than oral solid-dose production. Important failure points include aseptic processing, sterilization validation, particulate contamination, container defects and product stability.

Because total market demand is limited, manufacturers may discontinue a product after relatively modest quality or supply problems. This can create temporary shortages without producing a sustainable long-term market expansion.

How does tolazoline compare with modern pulmonary hypertension drugs?

Drug or therapy	Primary role	Relative position to tolazoline
Inhaled nitric oxide	Neonatal pulmonary vasodilation	Preferred modern therapy in appropriate neonates
Sildenafil	Pulmonary vasodilator	Used in selected pediatric and adult cases
Epoprostenol and related agents	Advanced pulmonary arterial hypertension	Stronger evidence and specialized use
Tolazoline	Historical nonselective vasodilator	Legacy or limited-use product
Xylazine reversal protocols	Veterinary sedation management	Tolazoline remains commercially relevant in horses

Tolazoline's disadvantage is not only age. Its nonselective pharmacology increases systemic adverse effects and makes dose management less attractive than targeted pulmonary therapies.

What generic launch risks exist for tolazoline hydrochloride?

A new generic or private-label entrant would face low patent risk but meaningful commercial risk.

Generic launch opportunities

no meaningful molecule patent barrier;
low clinical differentiation requirement for an established injectable;
potential access to veterinary distribution;
possibility of benefiting from supply shortages;
limited direct competition in some geographic markets.

Generic launch risks

small total market;
low unit volume;
sterile manufacturing expense;
limited pricing power;
uncertain human reference-product pathway;
procurement concentration among distributors;
possible substitution by other clinical protocols;
low return on regulatory investment.

The most viable strategy is usually a focused veterinary product rather than a broad human-market redevelopment program.

What licensing deals affect tolazoline hydrochloride?

No major recent licensing transaction centered on tolazoline hydrochloride is publicly established. The product is generally handled through manufacturing, distribution and private-label arrangements rather than strategic licensing.

A potential transaction would more likely involve:

an animal-health distributor acquiring supply rights;
a contract manufacturer producing sterile injectable product;
a regional marketing authorization;
an API supply agreement;
a portfolio transaction involving several mature veterinary products.

The absence of major licensing activity is consistent with tolazoline's low revenue ceiling and limited patent leverage.

What is the outlook for tolazoline hydrochloride through 2030?

The outlook is stable but commercially narrow.

Period	Expected market direction
2024-2025	Human demand remains marginal; veterinary demand remains established
2026-2027	Continued reliance on equine use and supply-chain execution
2028-2030	Low-growth or declining overall market unless a shortage or new use emerges

The strongest investment case is a low-capital, supply-focused veterinary strategy with existing sterile manufacturing capacity. The weakest case is a stand-alone human pharmaceutical development program requiring new clinical evidence.

Key Takeaways

Tolazoline hydrochloride is a mature, largely off-patent product.
Human use has declined because newer pulmonary and vascular therapies offer stronger clinical positioning.
The principal remaining commercial niche is veterinary injection for reversal of xylazine sedation in horses.
No material current Paragraph IV litigation or active human patent estate is associated with the product.
The main barriers are sterile manufacturing, regulatory compliance, supply reliability and limited market size.
Public companies do not generally disclose standalone tolazoline revenue.
Financial prospects are modest: stable niche veterinary demand, negligible human growth and limited potential for price expansion.
The strongest commercial model is veterinary distribution or contract manufacturing, not branded human redevelopment.

Frequently Asked Questions

Is tolazoline hydrochloride still used in humans?

Yes, but human use is limited and largely legacy-based. It has been displaced in most settings by inhaled nitric oxide, sildenafil, prostacyclin therapies and other modern interventions.

Is tolazoline hydrochloride FDA approved for horses?

Tolazoline injection has been marketed in the United States for veterinary use in horses, including reversal of xylazine-induced sedation, under FDA Center for Veterinary Medicine oversight.[5]

Does tolazoline hydrochloride have generic competition?

The active ingredient is long off patent. Competition exists through veterinary products, private-label supply and compounding channels, although the number of active commercial suppliers may vary by country and period.

Can tolazoline hydrochloride be used as a neonatal pulmonary hypertension drug?

It has historical and off-label precedent, but it is not the dominant modern therapy. Current neonatal treatment decisions generally prioritize evidence-supported pulmonary vasodilator strategies and intensive-care management.

Is tolazoline hydrochloride an attractive pharmaceutical acquisition target?

Only in a narrow context. It may have value within a veterinary injectable portfolio or a mature-product supply platform. Its standalone human-market revenue, patent protection and growth potential are insufficient for a typical specialty-pharma acquisition thesis.

References

U.S. Food and Drug Administration. (2019). Inhaled nitric oxide drug products for neonatal respiratory failure: Guidance for industry. FDA.
Abman, S. H., Hansmann, G., Archer, S. L., Ivy, D. D., Adatia, I., Chung, W. K., Hanna, B. D., et al. (2015). Pediatric pulmonary hypertension: Guidelines from the American Heart Association and American Thoracic Society. Circulation, 132(21), 2037-2099.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
U.S. Food and Drug Administration. (2024). Discontinued drugs. FDA.
U.S. Food and Drug Administration, Center for Veterinary Medicine. (2024). Animal Drugs @ FDA: Tolazine and tolazoline hydrochloride products. FDA.

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	99
DailyMed Link:	tolazoline hydrochloride at DailyMed

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	PRISCOLINE	tolazoline hydrochloride	INJECTABLE;INJECTION	006403-005	Feb 22, 1985		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Summary for tolazoline hydrochloride

Medical Subject Heading (MeSH) Categories for tolazoline hydrochloride

Anatomical Therapeutic Chemical (ATC) Classes for tolazoline hydrochloride